| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Found in roots, leaves, nut-hulls, bark and wood of walnut trees. Juglone (5-hydroxy-1,4-naphthoquinone) Juglans nigra refers to the black walnut tree, which is one of the most well-known sources of juglone -Research has focused on the hulls (the green outer covering of the walnut) because they have the highest concentrations. -Fresh hulls can contain juglone levels in the range of approximately 1–5% of the dry weight -Juglone can redox cycle to generate reactive oxygen species (ROS). -Increasing Bax, decreasing Bcl‑2, caspase activation, and MMP depolarization. -Modulation of MAPK pathways (including ERK, JNK, and p38) -May inhibit NF‑κB signaling -Cause DNA damage or stress that, in turn, leads to p53 pathway activation— Pin1 Inhibition –Pin1, a peptidyl-prolyl cis/trans isomerase, is frequently overexpressed in cancer. -ic50 maybe 5-10uM -For matching 5uM, crude estimate is 5mg consumption of juglone required which might be 1.5 g of black walnut hull material
|
| Source: CGL-CS |
| Type: |
| Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death). MAPK Pathways: The MAPK family includes several pathways, the most notable being: 1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival. 2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis. 3.p38 MAPK: Associated with inflammatory responses and apoptosis. Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations. Altered Expression Levels: Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival. Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling. The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers. Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion. |
| 5118- | JG, | Juglone induces apoptosis and autophagy via modulation of mitogen-activated protein kinase pathways in human hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | HepG2 |
| 5099- | JG, | Juglone induces ferroptosis in glioblastoma cells by inhibiting the Nrf2-GPX4 axis through the phosphorylation of p38MAPK |
| - | vitro+vivo, | GBM, | LN229 | - | vitro+vivo, | GBM, | T98G |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:105 Target#:181 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid